National assessment of recommendations from healthcare providers for smoking cessation among adults with cancer. (June 2022)

• Record Type: Journal Article
• Authors: Matulewicz, Richard S.; Feuer, Zachary; Birken, Sarah A.; Makarov, Danil V.; Sherman, Scott E.; Bjurlin, Marc A.; El Shahawy, Omar
• Is Part Of: Cancer epidemiology. Volume 78(2022)
• Publication Date: 2022-06
• Subjects: Smoking cessation -- Cancer diagnosis -- Counseling; Cancer -- Epidemiology -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Diagnosis -- Periodicals; Carcinogenesis -- Periodicals; 616.994005
• DOI: 10.1016/j.canep.2021.102088
• Languages: English
• ISSNs: 1877-7821

Abstract

Abstract: Cancer survivors benefit from evidence-based smoking cessation treatment. A crucial first step in this process is a clinician recommending that the patient quit smoking. However, contemporary delivery of advice to quit among patients with cancer is not well known. In a cross-sectional analysis of all adult smokers included in a prospective population-representative study of US adults, we analyzed the frequency that patients reported receiving advice to quit smoking from a healthcare professional according to reported cancer history (no cancer, tobacco-related cancer, non-tobacco related cancer history). Among an estimated 28.3 million smokers, 9.3% reported a history of cancer, 48.8% of which were tobacco-related cancers. In general, advice to quit was reported by more (67.8%) cancer survivors than those adults without any cancer (56.0%). After adjustment for sociodemographic factors, smokers with a non tobacco-related cancer (0.51, 95% CI 0.32–0.83) and those without any cancer history (0.43, 95% CI 0.30–0.63) were both less likely to report being advised to quit smoking than patients with a tobacco-related cancer history. Highlights: Smokers with a cancer diagnosis are more likely to be advised to quit smoking. One-third of smokers with cancer history did not receive cessation counseling. Smokers receiving cessation counseling were twice as likely to receive pharmacotherapy.